Aegerion Pharma (AEGR) Posts Smaller-than-Expected Q4 Loss

Aegerion Pharma (NASDAQ: AEGR) reported Q4 EPS of ($0.69), $0.20 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $49 million versus the consensus estimate of $47.74 million.

Chief Executive Officer Mary Szela commented, “I am encouraged by the purpose-driven intent of Aegerion’s Board of Directors, leadership team and employees to redefine Aegerion. We have begun executing our turnaround strategy using a roadmap focused on repairing immediate issues, realigning the cost structure, enhancing the Company’s pipeline and leveraging Aegerion’s capabilities to have a transformative impact. We believe this roadmap will help return Aegerion to future growth and, in turn, create value for our shareholders.”

2016 Financial Guidance

Aegerion issued the following financial guidance for 2016:

• Aegerion expects total full-year 2016 global net product sales to be between $160 million and $190 million.
• Aegerion expects full-year 2016 global net product sales of JUXTAPID to be between $120 million and $140 million.
• Aegerion expects full-year 2016 global net product sales of MYALEPT to be between $40 million and $50 million.
• Aegerion expects full-year 2016 total non-GAAP operating expenses to be between $145 million and $155 million, and GAAP operating expenses to be between $165 and $175 million. The Company’s non-GAAP operating expenses exclude the impact of expected stock-based compensation expenses of between $20 million and $25 million, cash and non-cash interest expense, and the purchase price accounting effects related to the fair value of assets acquired in the MYALEPT acquisition.
• Aegerion expects cash used from operations for the full year of 2016 to be between $10 million and $20 million.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• SunPower (SPWR) determined prior financial statements should no longer be relied upon
• Fiserv (FI) Tops Q1 EPS by 9c; Boosts outlook